New partnership to advance medical isotope production to treat prostate cancer

Bruce Power announced a partnership with Kinectrics and Framatome that will enable the production of medical isotopes to treat prostate cancer. Photo courtesy of Bruce Power.

Bruce Power is joining forces with Kinectrics and Framatome to advance an innovative project to enable the production of a key medical isotope used to treat prostate cancer known as Lutetium-177.

“This is a very exciting day as we mark the beginning of a new partnership that sets the groundwork for the production of an isotope that treats prostate cancer,” said Mike Rencheck, Bruce Power’s President and CEO. “We want to ensure Canada remains at the forefront of global isotope development and production. Today’s announcement is a big step forward.”

Innovation in targeted cancer therapies is creating a significant worldwide demand for life-saving isotopes like Lutetium-177. Utilizing the reactors at Bruce Power will help to ensure that this key medical isotope will be delivered to patients in Canada and around the world, reliably and affordably.

The partnership will focus on achieving production in 2022 following regulatory and other approvals. Bruce Power will also be working with all levels of government to progress a number of strategic export and business development opportunities connected with this project to align with several key public policy areas.

Read the full news release here.